Category - Markets

H.C. Wainwright slashed its price target for Mersana Therapeutics (NASDAQ:MRSN) to $16 from $33 after the company disclosed a partial clinical hold on its lead clinical program targeting HER2 expressing cancers. The...

H.C. Wainwright initiated coverage of Innovate Biopharmaceuticals (NASDAQ:INNT) with a “buy” rating and $35 price target. The stock finished at $8.08 on July 17. Innovate is focused on two clinical-stage assets aimed at...

William Blair launched coverage of Autolus Therapeutics (NASDAQ:AUTL) with an “outperform” rating and risk-adjusted valuation of roughly $38. The stock closed at $20.86 on July 17. “Based on our view, the company’s next...

BTIG initiated coverage of electroCore (NASDAQ:ECOR) with a “buy” rating and $20 price target. The stock closed at $14.64 on July 16. electroCore has developed an FDA-cleared non-invasive vagus nerve stimulation device...

H.C. Wainwright initiated coverage of Sol-Gel Technologies (NASDAQ:SLGL) with a “buy” rating and price target of $21. The stock closed at $6.97 on July 13. The company’s lead drug candidates, TWIN and VERED, are...

William Blair initiated coverage of Kezar Life Sciences (NASDAQ:KZR) with an “outperform” rating and fair value estimate of $25. The stock closed at $16.50 on July 13. Analyst Matthew Phipps writes the company’s novel...

H.C. Wainwright launched coverage of Adamas Pharmaceuticals (NASDAQ:ADMS) with a “buy” rating and $45 price target. The stock closed at $27.06 on July 13. Adamas’ lead product, GOCOVRI, was approved in August 2017 in...

Ladenburg Thalmann upgraded Vericel (NASDAQ:VCEL) to “buy” from “neutral” and introduced a price target of $13. The stock closed at $9.10 on July 13. “We believe Vericel shares are oversold and would be buyers of the...

Stifel launched coverage of Galmed Pharmaceuticals (NASDAQ:GLMD) with a “buy” rating and price target of $35. The stock closed at $12.77 on July 12. “We think Galmed’s lead, wholly-owned asset, Aramchol, has...

H.C. Wainwright initiated coverage of Syndax Pharmaceuticals (NASDAQ:SNDX) with a “buy” rating and a $30 price target. The stock closed at $7.10 on July 11. Analyst Edward White writes that Syndax’s lead candidate...